PWE-174 A Proof Of Concept Assessment Of Non-invasive Vagus Nerve Stimulation (nvns) With Gammacore® In Patients With Gastroparesis Awaiting Enterra® Implantation: Abstract PWE-174 Table 1

Jaboli, MF; Bennell, José; Epstein, Owen

doi:10.1136/gutjnl-2014-307263.434

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, VNS is also being investigated for bipolar disorder, Alzheimer's disease, obesity, impaired glucose tolerance, gastroparesis, asthma, fibromyalgia, traumatic brain injury, stroke (neuroprotection, neurogenesis), hemostasis, cerebellar tremor, and involuntary movement disorders …”

Section: Development Of Clinical Vnsmentioning

confidence: 99%

“…The optimal stimulation settings (number of stimulations per day, total stimulation duration) to reach a satisfactory response for each disorder remain to be determined. At the moment, the gammaCore device has been studied for the treatment of cluster headache, migraine, and hemicrania continua, and may also improve gastroparesis and asthma . In all of these studies, tcVNS was well tolerated without any major cardiac AEs …”

Section: Recent Progress In Noninvasive Vnsmentioning

confidence: 99%

See 1 more Smart Citation

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II

2015

View full text Add to dashboard Cite

The development of vagus nerve stimulation (VNS) began in the 19th century. Although it did not work well initially, it introduced the idea that led to many VNS-related animal studies for seizure control. In the 1990s, with the success of several early clinical trials, VNS was approved for the treatment of refractory epilepsy, and later for the refractory depression. To date, several novel electrical stimulating devices are being developed. New invasive devices are designed to automate the seizure control and for use in heart failure. Non-invasive transcutaneous devices, which stimulate auricular VN or carotid VN, are also undergoing clinical trials for treatment of epilepsy, pain, headache, and others. Noninvasive VNS (nVNS) exhibits greater safety profiles and seems similarly effective to their invasive counterpart. In this review, we discuss the history and development of VNS, as well as recent progress in invasive and nVNS.

show abstract

Section: Development Of Clinical Vnsmentioning

confidence: 99%